Logotype for Stablecoin Development Corporation

Stablecoin Development Corporation (SDEV) Q2 2023 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Stablecoin Development Corporation

Q2 2023 earnings summary

10 Nov, 2026

Executive summary

  • Q2 revenue was $4.6M, up 26% YoY, driven by record wound care sales; operating loss narrowed 37% as expenses were managed.

  • Digital marketing efficiency supported lower sales and marketing costs while eye care, skin care, and wound care each contributed to sales.

Financial highlights

  • Q2 net product revenue was $4.6M; gross margin held at 50% YoY, while operating expenses declined 8%.

  • Sales and marketing expense fell 16% to $1.7M; G&A was $1.9M, consistent YoY.

  • Operating loss was $1.4M, improving 37% YoY; net loss was $4.0M, or $1.27/share, including a $2.0M non-cash retained earnings reduction tied to the preferred-stock down-round feature.

  • First-half revenue rose 11% to $7.7M; operating loss improved 32% to $3.1M, while net loss was $5.8M, or $2.21/share.

Outlook and guidance

  • Eye care is expected to deliver incremental growth for the remainder of 2023, particularly through online sales.

  • DERMAdoctor strategy shifts toward profitability by focusing on top-selling products and efficient channels, reducing development investment and closing inefficient channels.

  • The Q2 $1M NeutroPhase order is not expected to repeat in Q3; a smaller order is anticipated in Q4.

  • Second-half gross margin is expected to be around 55%, as wound care's lower margin moderated the mix.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Stablecoin Development Corporation